Squamous lung carcinoma data add further weight to promise of Oncolytics' Reolysin
This article was originally published in Scrip
The day after Oncolytics Biotech said it would split the first Phase III clinical trial for Reolysin - the Canadian company's proprietary formulation of human reovirus - into two separate patient groups, it announced positive interim results from a Phase II trial in squamous cell carcinoma of the lung (SCCLC) that justified continuation of the 55-patient study.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.